Suppression of thyroid function by interferon-alpha 2 in man
- PMID: 1944608
- DOI: 10.1007/BF00184300
Suppression of thyroid function by interferon-alpha 2 in man
Abstract
Profound biological changes occur in patients treated with interferon. Observations of endocrine changes prompted us to examine the effects of subcutaneous alpha-interferon administration in single doses on circulating levels of thyroid stimulating hormone, total thyroxine, and total triiodothyronine in 10 volunteers (5 healthy subjects and 5 patients with hepatitis C). Blood samples were taken on an out-patient basis immediately before and 2, 12, 24, 48, and 72 h after administration of 1, 3, or 5 x 10(6) units of recombinant alpha-interferon. Application of the different dose levels was randomly assigned. Plasma samples were stored at -80 degrees C; after collection of samples had been completed hormone levels were measured using commercially available test kits. At all time points before and after injection of alpha-interferon, standard deviations of measured hormone levels of healthy control subjects and patients overlapped to a considerable extent. At a dose level of 5 x 10(6) units, alpha-interferon significantly increased cortisol levels as described, and decreased the level of thyroid stimulating hormone in the group receiving alpha-interferon as compared to placebo-treated healthy volunteers. The effects occurred 12 h after injection. Maximum suppression of thyroid stimulating hormone levels was observed 24 h after injection, when serum levels of thyroxine and triiodothyronine also were significantly reduced. We conclude that subcutaneous alpha-interferon treatment with doses as low as 5 x 10(6) units affects the control of thyroid function.
Similar articles
-
Effects of obesity, total fasting and re-alimentation on L-thyroxine (T4), 3,5,3'-L-triiodothyronine (T3), 3,3',5'-L-triiodothyronine (rT3), thyroxine binding globulin (TBG), cortisol, thyrotrophin, cortisol binding globulin (CBG), transferrin, alpha 2-haptoglobin and complement C'3 in serum.Acta Endocrinol (Copenh). 1979 Aug;91(4):629-43. doi: 10.1530/acta.0.0910629. Acta Endocrinol (Copenh). 1979. PMID: 115194
-
Effect of ACTH-stimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH-response to TRH.Acta Med Acad Sci Hung. 1979;36(4):381-94. Acta Med Acad Sci Hung. 1979. PMID: 233400
-
Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men.J Clin Endocrinol Metab. 1995 Nov;80(11):3140-4. doi: 10.1210/jcem.80.11.7593416. J Clin Endocrinol Metab. 1995. PMID: 7593416
-
Plasma thyroid hormones and prolactin in premature infants and their mothers after prenatal treatment with thyrotropin-releasing hormone.Pediatr Res. 1992 Dec;32(6):673-8. doi: 10.1203/00006450-199212000-00009. Pediatr Res. 1992. PMID: 1287557 Clinical Trial.
-
Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.J Clin Endocrinol Metab. 2001 Apr;86(4):1660-4. doi: 10.1210/jcem.86.4.7405. J Clin Endocrinol Metab. 2001. PMID: 11297600
Cited by
-
Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.Clin Investig. 1994 Dec;72(12):975-8. doi: 10.1007/BF00577739. Clin Investig. 1994. PMID: 7711430 Clinical Trial.
-
Clinical toxicity of the interferons.Drug Saf. 1994 Feb;10(2):115-50. doi: 10.2165/00002018-199410020-00003. Drug Saf. 1994. PMID: 7516663 Review.
-
Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue.Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):322-8. doi: 10.1007/BF00175039. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 7824050